2023 Q2 Form 10-Q Financial Statement

#000095017023013868 Filed on April 21, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $7.773M $7.824M
YoY Change 1.83% 7.8%
Cost Of Revenue $2.143M $2.067M
YoY Change -2.65% -1.7%
Gross Profit $5.630M $5.757M
YoY Change 3.64% 11.67%
Gross Profit Margin 72.43% 73.58%
Selling, General & Admin $4.039M $3.879M
YoY Change 3.23% 14.9%
% of Gross Profit 71.75% 67.38%
Research & Development $304.7K $78.83K
YoY Change 276.63% -46.45%
% of Gross Profit 5.41% 1.37%
Depreciation & Amortization $354.9K $370.0K
YoY Change -2.66% -6.6%
% of Gross Profit 6.31% 6.43%
Operating Expenses $4.602M $3.958M
YoY Change 15.23% 12.33%
Operating Profit $1.028M $1.683M
YoY Change -13.94% 14.47%
Interest Expense -$683.6K $466.2K
YoY Change -347.19% 52.32%
% of Operating Profit -66.5% 27.7%
Other Income/Expense, Net $2.070K -$468.6K
YoY Change -100.7% 48.9%
Pretax Income $346.4K $1.215M
YoY Change -61.5% 5.09%
Income Tax $125.4K $447.7K
% Of Pretax Income 36.21% 36.86%
Net Earnings $221.0K $766.8K
YoY Change -65.18% -7.84%
Net Earnings / Revenue 2.84% 9.8%
Basic Earnings Per Share $0.03 $0.09
Diluted Earnings Per Share $0.03 $0.09
COMMON SHARES
Basic Shares Outstanding 8.304M 8.443M
Diluted Shares Outstanding 8.332M 8.475M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.692M $2.213M
YoY Change -40.99% -15.42%
Cash & Equivalents $1.124M $1.373M
Short-Term Investments $568.2K $840.3K
Other Short-Term Assets $1.060M $421.1K
YoY Change 25.42% -12.92%
Inventory $879.3K $900.1K
Prepaid Expenses $650.5K $580.1K
Receivables $6.682M $6.522M
Other Receivables $0.00 $0.00
Total Short-Term Assets $10.31M $10.64M
YoY Change 0.08% 9.46%
LONG-TERM ASSETS
Property, Plant & Equipment $18.29M $14.43M
YoY Change 353.98% 279.17%
Goodwill $1.941M $1.941M
YoY Change 0.0% 0.0%
Intangibles $1.415M $1.439M
YoY Change -6.38% -6.28%
Long-Term Investments $308.0K $308.0K
YoY Change 0.0% 0.0%
Other Assets $36.49M $41.07M
YoY Change -11.13% -0.52%
Total Long-Term Assets $58.44M $55.50M
YoY Change 29.62% 23.08%
TOTAL ASSETS
Total Short-Term Assets $10.31M $10.64M
Total Long-Term Assets $58.44M $55.50M
Total Assets $68.76M $66.13M
YoY Change 24.12% 20.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.056M $2.364M
YoY Change 135.48% 27.93%
Accrued Expenses $2.441M $3.075M
YoY Change 17.66% 46.15%
Deferred Revenue $9.456M $9.253M
YoY Change 1.77% 2.16%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $158.5K $158.5K
YoY Change -55.72% -85.97%
Total Short-Term Liabilities $19.71M $18.91M
YoY Change 25.44% 15.41%
LONG-TERM LIABILITIES
Long-Term Debt $8.506M $8.548M
YoY Change
Other Long-Term Liabilities $41.40M $47.91M
YoY Change 17.36% 40.21%
Total Long-Term Liabilities $49.91M $47.91M
YoY Change 41.48% 40.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.71M $18.91M
Total Long-Term Liabilities $49.91M $47.91M
Total Liabilities $69.62M $66.82M
YoY Change 36.53% 32.17%
SHAREHOLDERS EQUITY
Retained Earnings -$20.65M -$20.87M
YoY Change 35.24% 31.23%
Common Stock $43.22M $43.06M
YoY Change 3.1% 3.02%
Preferred Stock
YoY Change
Treasury Stock (at cost) $23.42M $22.88M
YoY Change 5.33% 5.7%
Treasury Stock Shares $6.561M $6.405M
Shareholders Equity -$858.4K -$687.5K
YoY Change
Total Liabilities & Shareholders Equity $68.76M $66.13M
YoY Change 24.12% 20.66%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income $221.0K $766.8K
YoY Change -65.18% -7.84%
Depreciation, Depletion And Amortization $354.9K $370.0K
YoY Change -2.66% -6.6%
Cash From Operating Activities $1.989M $1.644M
YoY Change 2.15% 9.1%
INVESTING ACTIVITIES
Capital Expenditures $1.457M $375.6K
YoY Change -574.78% -42.0%
Acquisitions
YoY Change
Other Investing Activities -$117.5K -$826.3K
YoY Change -130.05% -84.71%
Cash From Investing Activities -$1.575M -$1.202M
YoY Change -1972.96% -80.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -663.2K -772.8K
YoY Change -51.64% -50.84%
NET CHANGE
Cash From Operating Activities 1.989M 1.644M
Cash From Investing Activities -1.575M -1.202M
Cash From Financing Activities -663.2K -772.8K
Net Change In Cash -249.1K -330.9K
YoY Change -137.75% -94.59%
FREE CASH FLOW
Cash From Operating Activities $1.989M $1.644M
Capital Expenditures $1.457M $375.6K
Free Cash Flow $531.7K $1.268M
YoY Change -76.41% 47.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000862692
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-02-28
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-40767
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
CRYO-CELL INTERNATIONAL, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
22-3023093
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
700 Brooker Creek Blvd
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Oldsmar
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
34677
CY2023Q1 dei City Area Code
CityAreaCode
813
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
749-2100
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
CY2023Q1 dei Trading Symbol
TradingSymbol
CCEL
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NYSEAMER
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8303604
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1373099
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1703958
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
840277
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
17620
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3580233
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3528119
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6522456
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6043941
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
580144
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
566557
CY2023Q1 us-gaap Inventory Net
InventoryNet
900052
CY2022Q4 us-gaap Inventory Net
InventoryNet
851230
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
421083
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
426879
CY2023Q1 us-gaap Assets Current
AssetsCurrent
10637111
CY2022Q4 us-gaap Assets Current
AssetsCurrent
9610185
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14426725
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13603115
CY2023Q1 ccel Duke License Agreement
DukeLicenseAgreement
13450834
CY2022Q4 ccel Duke License Agreement
DukeLicenseAgreement
13691028
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1439217
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1463312
CY2023Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
8996063
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
9275344
CY2023Q1 us-gaap Goodwill
Goodwill
1941411
CY2022Q4 us-gaap Goodwill
Goodwill
1941411
CY2023Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
13742399
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
13742399
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
526710
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
606034
CY2023Q1 ccel Deposits And Other Assets
DepositsAndOtherAssets
665565
CY2022Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
647226
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
41070199
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
41674754
CY2023Q1 us-gaap Assets
Assets
66134035
CY2022Q4 us-gaap Assets
Assets
64888054
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2363757
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1605301
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3074903
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3585810
CY2023Q1 us-gaap Notes Payable Current
NotesPayableCurrent
158456
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
150527
CY2023Q1 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
1772728
CY2022Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
2272728
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
288902
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
297691
CY2023Q1 ccel Duke License Agreement Liability Current
DukeLicenseAgreementLiabilityCurrent
2000000
CY2022Q4 ccel Duke License Agreement Liability Current
DukeLicenseAgreementLiabilityCurrent
1983036
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9253131
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9586327
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
18911877
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19481420
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
37246889
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
36000059
CY2023Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
998003
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
1162704
CY2023Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
8547744
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8579875
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
242039
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
313298
CY2023Q1 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
875000
CY2022Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
875000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
47909675
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
46930936
CY2023Q1 us-gaap Liabilities
Liabilities
66821552
CY2022Q4 us-gaap Liabilities
Liabilities
66412356
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14848001
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8443230
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14848001
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8500511
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
148480
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
148480
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
42910554
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
42597380
CY2023Q1 us-gaap Treasury Stock Value
TreasuryStockValue
22875850
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
22632649
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-20870701
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-21637513
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-687517
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1524302
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66134035
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
64888054
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7824415
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7258531
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2067364
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2103202
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3878903
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3375954
CY2023Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-164701
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-116433
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
78834
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
147220
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
280844
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
278166
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
6141244
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
5788109
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1683171
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1470422
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-3681
CY2022Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-8642
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1268
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9
CY2023Q1 us-gaap Interest Expense
InterestExpense
466231
CY2022Q1 us-gaap Interest Expense
InterestExpense
306095
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-468644
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-314728
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1214527
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1155694
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
447715
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
323647
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
766812
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
832047
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.10
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8467074
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8527031
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8474737
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8748183
CY2023Q1 us-gaap Profit Loss
ProfitLoss
766812
CY2022Q1 us-gaap Profit Loss
ProfitLoss
832047
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
369950
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
396112
CY2023Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-164701
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-116433
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-3681
CY2022Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-8642
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
313174
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
31896
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
186904
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
164388
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
5444
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
6389
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
79324
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
76604
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
665419
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
62780
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
13587
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-20687
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-230459
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-33636
CY2023Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-5796
CY2022Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-227666
CY2023Q1 ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
18339
CY2022Q1 ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
17594
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
221749
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
357959
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-510907
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-953433
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-80048
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-76255
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
913634
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
577228
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1643926
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1506759
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
375600
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
647637
CY2023Q1 ccel Payment Of Duke License Agreement
PaymentOfDukeLicenseAgreement
0
CY2022Q1 ccel Payment Of Duke License Agreement
PaymentOfDukeLicenseAgreement
5000000
CY2023Q1 ccel Payments To Acquire Marketable Securities And Other Investments
PaymentsToAcquireMarketableSecuritiesAndOtherInvestments
1017738
CY2022Q1 ccel Payments To Acquire Marketable Securities And Other Investments
PaymentsToAcquireMarketableSecuritiesAndOtherInvestments
405599
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
191400
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1201938
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6053236
CY2023Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
243201
CY2022Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
828980
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
29646
CY2022Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
775000
CY2023Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
500000
CY2022Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-772847
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1571980
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-330859
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-6118457
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1703958
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8263088
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1373099
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2144631
CY2023Q1 ccel Construction Costs Payable
ConstructionCostsPayable
536707
CY2022Q1 ccel Construction Costs Payable
ConstructionCostsPayable
0
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
441336
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
247081
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
33072
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
644
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1524302
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
313174
CY2023Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
243201
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
766812
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-687517
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
4184314
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
32000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
31896
CY2022Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
828980
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
832047
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
4251277
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2023Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
46500020
CY2023Q1 ccel Revenue Remaining Performance Obligation Next Twelve Months
RevenueRemainingPerformanceObligationNextTwelveMonths
9253131
CY2023Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2012Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
75000
CY2017Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
100000
CY2017Q2 ccel Reimbursement Of Personal Expenses
ReimbursementOfPersonalExpenses
10000
CY2023Q1 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
10432
CY2022Q1 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
15152
CY2023Q1 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
26436
CY2022Q1 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
24589
CY2023Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
633966
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
615628
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6522456
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6043941
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9253131
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9586327
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
37246889
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
36000059
CY2022Q1 ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
CY2023Q1 ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
615628
CY2023Q1 ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
26436
CY2023Q1 ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
8098
CY2023Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
633966
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6043941
CY2023Q1 ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
10373235
CY2023Q1 ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
9894720
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6522456
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
45586386
CY2023Q1 ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
6404429
CY2023Q1 ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
5490795
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
46500020
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
535522
CY2022Q1 ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
24589
CY2022Q1 ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
6995
CY2022Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
553116
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5253173
CY2022Q1 ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
8749914
CY2022Q1 ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
8851522
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5151565
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
40632910
CY2022Q1 ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
3997047
CY2022Q1 ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
3419819
CY2022Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
41210138
CY2022Q1 us-gaap Interest Expense
InterestExpense
306095
CY2023Q1 us-gaap Assets
Assets
66134035
CY2022Q4 us-gaap Assets
Assets
64888054
CY2023Q1 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2023Q1 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2022Q1 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2023Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
8706200
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
8730402
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
313000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32000
CY2023Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-4000
CY2022Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-9000
CY2023Q1 us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product Warranty and Cryo-Cell Cares</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Program</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February 1, 2012, the Company increased the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> payment warranty to a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> payment warranty to all of its new clients. Effective June 1, 2017, the Company increased the payment warranty to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to all new clients who choose the premium processing method, PrepaCyte CB. The product warranty is available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As discussed above, the Company has determined that the payment warranty represents variable consideration payable to the customer. In accordance with ASC 606, the Company has concluded the payment warranty be fully constrained under the most likely amount method; therefore, the transaction price does not reflect any expectation of service level credits at February 28, 2023 and November 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. At the end of each reporting period, the Company shall update the estimated transaction price related to the payment guarantee including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period.</span></p>
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
CY2017Q2 ccel Increased Payment Warranty
IncreasedPaymentWarranty
100000
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7824415
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7258531
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2067364
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2103202
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1683171
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1470422
CY2023Q1 us-gaap Interest Expense
InterestExpense
466231
CY2023Q1 ccel Inventory Collection Kits
InventoryCollectionKits
39738
CY2022Q4 ccel Inventory Collection Kits
InventoryCollectionKits
41463
CY2023Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2023Q1 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
9896115
CY2022Q4 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
10126574
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1439217
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1463312
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
24000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
24000
CY2023Q1 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
548085
CY2023Q1 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
0
CY2022Q1 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
6389
CY2023Q1 us-gaap Ratio Of Indebtedness To Net Capital1
RatioOfIndebtednessToNetCapital1
3.50
CY2023Q1 ccel Minimum Debt Service Coverage Ratio
MinimumDebtServiceCoverageRatio
1.25
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
8706200
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
8730402
CY2023Q1 us-gaap Notes Payable Current
NotesPayableCurrent
158456
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
150527
CY2023Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
8547744
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8579875
CY2023Q1 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
207919
CY2022Q1 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
18535
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
766812
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
832047
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8467074
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8527031
CY2023Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
7663
CY2022Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
221152
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8474737
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8748183
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.10
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
887314
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11484
CY2023Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
442314
CY2023Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P4Y6M14D
CY2023Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
7.42
CY2023Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
320671
CY2023Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
7.48
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
95486
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.42
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
113000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.19
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
86843
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
3.17
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
0
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
0
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
121643
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.24
CY2011Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000
CY2012Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
6000000
CY2016Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
8000000
CY2023Q1 us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
CY2023Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
6404771
CY2022Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
6347490
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
526710
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
606034
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
288902
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
297691
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
242039
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
313298
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
530941
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
610989
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
228878
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
295086
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
24591
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
17614
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
530941
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M29D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y29D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.035
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.035
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
88395
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
85964

Files In Submission

Name View Source Status
0000950170-23-013868-index-headers.html Edgar Link pending
0000950170-23-013868-index.html Edgar Link pending
0000950170-23-013868.txt Edgar Link pending
0000950170-23-013868-xbrl.zip Edgar Link pending
ccel-20230228.htm Edgar Link pending
ccel-20230228.xsd Edgar Link pending
ccel-ex31_1.htm Edgar Link pending
ccel-ex31_2.htm Edgar Link pending
ccel-ex31_3.htm Edgar Link pending
ccel-ex32_1.htm Edgar Link pending
ccel-20230228_cal.xml Edgar Link unprocessable
ccel-20230228_lab.xml Edgar Link unprocessable
ccel-20230228_pre.xml Edgar Link unprocessable
ccel-20230228_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ccel-20230228_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending